A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A23...
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease pro...
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function....
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
In this study, researchers will learn more about the use of felzartamab in participants with immunoglobulin A nephropathy (IgAN). This study will focus on participants who have protein in their urine ...
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO) therapy in participants with primary IgA nephropa...
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (...
Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO® (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have comple...
Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. T...
Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy and safety of Avacopan together with low-dose glucocorticoid in the treatment of patients with crescentic Imunoglobulin A Nephropathy (IgAN) and h...
Top Cities for IgA Nephropathy Clinical Trials
IgA Nephropathy clinical trials are recruiting across 49 cities. Here are the cities with the most active studies:
About IgA Nephropathy
IgA nephropathy is the most common form of glomerulonephritis worldwide, caused by deposits of immunoglobulin A in the kidneys. It can lead to kidney inflammation and progressive kidney damage. Treatment includes blood pressure management, immunosuppression, and newer targeted therapies.
Clinical trials are advancing new treatments for iga nephropathy. Currently, 9 studies are recruiting a combined 2,855 participants across the United States. Research is being conducted by 8 organizations including Novartis Pharmaceuticals, Alexion Pharmaceuticals, Inc., Alpine Immune Sciences Inc, A Subsidiary of Vertex and 5 others.
2026 IgA Nephropathy Research Landscape
As of March 2026, the iga nephropathy clinical trial landscape includes 9 actively recruiting studies across 49 cities in the United States. These studies are collectively seeking 2,855 participants, with an average enrollment target of 317 per study.
Research is being led by 8 different organizations, including Novartis Pharmaceuticals, Alexion Pharmaceuticals, Inc., Alpine Immune Sciences Inc, A Subsidiary of Vertex, Biogen, Hoffmann-La Roche, and 3 others.
Geographically, iga nephropathy trials are most concentrated in Los Angeles, California (7 trials); San Francisco, California (4 trials); Glendale, Arizona (3 trials); San Dimas, California (3 trials); Orange, California (3 trials) and 7 other cities.
Featured IgA Nephropathy Studies
Highlighted recruiting studies for iga nephropathy, selected by enrollment size and research scope.
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are recei...
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants with IgAN who are at risk of disease progression.
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the efficacy of povetacicept in adult participants compared with placebo in reducing proteinuria and preserving renal function.
Frequently Asked Questions About IgA Nephropathy Clinical Trials
Are there iga nephropathy clinical trials near me?
Yes, there are 9 iga nephropathy clinical trials currently recruiting across 49+ cities in the United States, including Los Angeles, California; San Francisco, California; Glendale, Arizona. Browse the studies above to find one at a location convenient for you.
How do I join a iga nephropathy clinical trial?
To join a iga nephropathy clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are iga nephropathy clinical trials free?
Yes, participation in iga nephropathy clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of iga nephropathy treatments are being studied?
Current iga nephropathy clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 8 research organizations.
Is it safe to participate in iga nephropathy clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov